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Abstract
Background:  Cysteinyl leukotrienes are potent inflammatory mediators implicated in the
pathogenesis of asthma. Human cysteinyl leukotriene receptor 1 (CYSLTR1) gene contains five
exons that are variably spliced. Within its promoter few polymorphisms were described. To date,
there has been no evidence about the expression of different splice variants of CysLT1 in asthma
and their association with CYSLTR1 promoter polymorphisms.
The goal of our study was to investigate CysLT1 alternative transcripts expression in asthmatic
patients with different CYSLTR1 promoter haplotypes.
The study groups consisted of 44 patients with asthma, diagnosed according to GINA 2008 criteria
and 18 healthy subjects. Genomic DNA and total RNA was extracted from peripheral blood
mononuclear cells. Real-time PCR was performed with specific primers for transcript I
[GenBank:DQ131799] and II [GenBank:DQ131800]. Fragments of the CYSLTR1 promoter were
amplified by PCR and sequenced directly to identify four single nucleotide polymorphisms: C/T
[SNP:rs321029], A/C [SNP:rs2637204], A/G [SNP:rs2806489] and C/T [SNP:rs7066737].
Results: The expression of CysLT1 transcript I and II in asthma did not differ from its expression
in healthy control group. However, in major alleles homozygotic CAAC/CAAC women with
asthma we found significantly higher expression of transcript I as compared to heterozygous
CAAC/TCGC women in that loci. CysLT1 transcript I expression tended to negative correlation
with episodes of acute respiratory infection in our asthmatic population. Moreover, expression of
CysLT1 transcript II in CAAC/CAAC homozygotic women with asthma was significantly lower than
in CAAC/CAAC healthy control females.
Conclusions: Genetic variants of CYSLTR1 promoter might be associated with gender specific
expression of CysLT1 alternative transcripts in patients with asthma. CysLT1  splice variants
expression might also correlate with the susceptibility to infection in asthmatic population.
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Background
Asthma is a complex disease influenced by genetic and
environmental factors [1], with highly variable clinical
spectrum, but with the consistent presence of airway
inflammation. Among many important inflammatory
mediators involved in its pathogenesis are cysteinyl leuko-
trienes. They are potent lipid mediators derived from the
lipooxygenase pathway of arachidonic acid metabolism
[2,3]. They are products of activated eosinophils, mast
cells, basophils and macrophages [3,4]. Originally identi-
fied as potent mediators of bronchoconstriction, mucus
secretion, and airway hyperresponsiveness [2,5], they are
now also described as important factors of innate and
adaptive immune responses [6], as well as in the effector
phase of inflammation, tissue repair and fibrosis [7,8]. So
far, three cysteinyl leukotrienes receptors have been iden-
tified: CysLT1[9,10], CysLT2  [11-13] and recently
described GPR17 [14]. All of them are seven transmem-
brane-spanning receptors that couple to G proteins
(GPCR) and activate various intracellular signaling path-
ways [15]. The distribution of these three types of CysLTs
receptors is diverse and depends on the cells and tissues as
well as on the pathophysiologic conditions. In human
lungs CysLT1 protein was demonstrated in the smooth
muscle cells at all levels of the respiratory tract, interstitial
lung macrophages and in the epithelial cells as well as in
infiltrating inflammatory cells such as monocytes/macro-
phages, mast cells, eosinophils, CD 34+ cells, neutrophils
and B lymphocytes [9,10,16,17]. CysLT1  mRNA was
observed in normal and asthmatic human lungs [10,16].
However, recent studies have shown a significant increase
in CysLT1 positive cells in the bronchi of stable asthmatics
in comparison to healthy, non smoking controls and fur-
ther elevation of CysLT1 mRNA and protein in acute severe
exacerbations of asthma [18]. Nevertheless, response to
leukotriene antagonists (LTRA) in asthma is known to be
variable and it still has not been determined which of the
phenotypes benefits most from this type of treatment [19-
21]. Moreover, there is still a discrepancy about the precise
location of the CYSLTR1 promoter region and the exon/
intron structure of this gene [22,23]. Therefore, there is a
possibility that at least two alternative promoters exist and
might initiate different transcripts of the receptor gene in
various pathophysiological conditions [22]. Furthermore,
functional and case-control studies of the CYSLTR1 gene
contribution to asthma have shown inconsistent results
[22,24,25]. We have also previously observed [26] that
some clinical features of severe asthma were associated
with the minor [TCGC] haplotype of CYSLTR1 promoter
SNPs in severe asthmatic women. However, we have
found no significant differences in gene reporter activity
among all tested promoter SNPs constructs. Therefore in
this study we hypothesized that CYSLTR1 gene promoter
polymorphisms might influence on the expression of
CysLT1 alternative transcripts, which might further influ-
ence on the course of the disease. To test this hypothesis,
we analyze the expression of CysLT1 alternative transcripts
in patients with asthma and in healthy control group with
the relevance to the CYSLTR1 gene promoter polymor-
phisms. We demonstrate here that there is no difference in
the expression of CysLT1 alternative transcripts between
asthmatic and healthy population analyzed without focus
on genetic background and sex stratification.
However, there is a difference in the CysLT1 alternative
transcripts expression in women with asthma with differ-
ent promoter haplotypes. Furthermore, we also demon-
strate that the expression of certain splice variants
correlates with the episodes of acute infections.
Materials
Study population
The study involved 44 patients with persistent asthma
randomly selected from asthmatic group treated in the
Outpatient Unit of the Department of Immunology,
Rheumatology and Allergy in Lodz, Poland. The sex
matched healthy individuals group consisted of 18 unre-
lated, non-atopic subjects with a negative family history of
allergy and asthma. Asthma was defined by a specialist of
respiratory diseases according to GINA 2008 criteria [27].
Atopy was defined as one or more positive reactions in the
skin prick tests with the battery of inhaled allergens. The
aspirin intolerant asthma phenotype was defined in
patients having a proven history of asthma aggravation on
exposure to aspirin/NSAIDs and a positive response in a
lysine-aspirin bronchoprovocation test. Exacerbations
were defined as acute worsening of asthma symptoms
with decrease of FEV1 or PEF ≥ 20% diagnosed by the doc-
tor and put in the case history as a word "exacerbation",
with hospitalization or urgent visit for asthma or stated
aggravation of asthma symptoms requiring at least dou-
bling the dose of ICS or addition or periodic increase of
oral GCS. Episodes of acute respiratory tract infection
were defined as acute aggravation of patient's health with
fever, yellow sputum and need for antibiotic usage with or
without asthma exacerbation. Nocturnal dyspnoea was
characterised and stated in the case history by the doctor
according to the interview with the patient. Chronic rhi-
nosinusitis was diagnosed on the basis of patients' symp-
toms and CT scans. Allergic rhinitis was defined according
to ARIA 2008 criteria [28]. GERD was diagnosed accord-
ing to American College of Gastroenterology 2005 recom-
mendations [29]. The doses of ICS were calculated as the
budesonide equivalent within the whole period of obser-
vation in the Outpatient Unit and divided by the number
of observation days and presented as micrograms per day.
Some patients received ICS by nebulization. The doses of
systemic GCS were calculated as a prednisone equivalent.
GCS, montelukast and zafirlukast were also divided by the
number of whole days of observation and presented asBMC Immunology 2009, 10:63 http://www.biomedcentral.com/1471-2172/10/63
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milligrams per day. These drugs were prescribed to the
patients for certain periods e.g. 2-3 weeks in regards of
GCS in decreasing dosage in case of exacerbation or 3-4
months in regards of leukotriene receptor antagonists in
case of worse asthma control and there were periods free
of certain drugs. Therefore, median dose of certain drug
per day includes periods without this drug usage. Thus,
the dose of the drug could be lower than available and
commonly used doses.
Clinical features of patients were analysed retrospectively
over the whole period of observation using individually
self-created database software, with the possibility of cal-
culations of studied variables.
Characteristics of the studied groups are presented in
Table 1. The study was approved by the Ethics Committee
of the Medical University of Lodz and informed consent
was obtained from every subject prior to the study.
Genomic DNA Preparation and Single Nucleotide 
Polymorphisms (SNPs) Genotyping
Genomic DNA was extracted from peripheral blood
mononuclear cells of studied subjects using Genomic
Maxi AX (A&A, Gdansk, Poland). A 633 bp fragment con-
taining [SNP:rs321029] C/T, [SNP:rs2637204] A/C was
obtained with the following primers: 5'-AGCCTTTTCCTT-
TCTGGTTC-3'(forward) and 5'-TCACCATCACCAC-
CACAATC-3'(reverse) (Tib Molbiol, Poznan, Poland). A
602 bp fragment containing the [SNP:rs2806489] A/G
and [SNP:rs70667337] C/T was amplified with the fol-
lowing primers: 5'-GAGCAGGGCACATTTGCTAG-3'(for-
ward) and 5'-GCAAGCCCAGTCATTCCAGA-3'(reverse)
(Tib Molbiol). Primer design and optimization of anneal-
ing temperatures were performed with MacVector soft-
ware (Oxford Molecular Group, Madison, WI). PCR
condition were as follows: initial 5 min at 95°C followed
by 35 cycles of 30 s at 94°C, 30 s at 58°C, 45 s at 72°C
and 7 min at 72°C. The PCR reactions were performed in
Biometra T3 thermocycler (Biometra, Göttingen, Ger-
many). These PCR fragments were purified with Clean-Up
(A&A) and labeled using fluorescently labeled dye termi-
nators technique (Applied Biosystems, Foster City, CA)
with specific nested primers. To analyze sequence includ-
ing rs321029 and rs2637204, following primers were
used: 5'-ACATCAAAGTGCTGCCCCAG-3' and for
sequence including rs2806489 and rs70667337: 5'-
GGAACCAGAAAGGAAAAGGC-3' (Eurogentec, Polgen,
Lodz, Poland) and appropriate primers from PCR in case
of samples from female subjects which were sequenced in
both directions. Second purification step was performed
using ExTerminator kit (A&A). All sequencing reactions
were performed in ABI Prism 310 capillary sequencer
(Applied Biosystems).
Real-Time PCR analysis of alternative transcripts 
expression
Peripheral blood mononuclear cells were isolated from
the blood using Histopaque 1077 (Sigma-Aldrich,
Poland) density gradient centrifugation. Total RNA was
isolated from peripheral blood mononuclear cells using
the Total RNA Extraction Kit (A&A) according to manufac-
turer's protocol in the presence of RQ1 RNase-Free DNase
(Promega, Madison, WI, USA). Total RNA (2 μg) was
reverse-transcribed using the random hexamers and
ImProm-II™ reverse transcription system (Promega) in a
volume of 25 μl at 37°C for 90 min. All real-time PCR
reactions were optimized to obtain the best amplification
kinetics. Amplification reactions were performed in a final
volume of 20 μl using qPCRTM Core Kit for SybrTM
Green I w/o dUTP (EUROGENTEC, Seraing, Belgium),
250 nM primers and 25 ng cDNA template per reaction.
Nuclease free water was used as a no-template control.
The following primer pairs were used: for CysLT1 tran-
script I [GenBank:DQ131799]: forward 5'-AACG-
CAAAAGGACAGTAAACTGTG-3' and reverse 5'-
ATCAATGCCTTTTACGGTGTAATATTAG-3'; for CysLT1
transcript II [GenBank:DQ131800]: forward 5'-
TCGAATTTACTGAAGACTTGGAGCTTGCTTC-3' and
reverse 5'-TCTCTACGAATGTCTGCTTTGTGCCTGC-3',
for RPS17: 5'-ACCCCAATGTCAAGGAGATCAAGGTC-
Table 1: Characteristics of the studied groups
Asthma Controls
n 44 18
Men/women [n] 19/25 11/7
Age [years] 53 (21-77) 41(20-71)
Period of observation [months] 62 (9-124) n.a.
FEV1 [%] 79 (37-113) n.a.
PEF [l/s] 365 (223-610) n.a.
Exacerbations per year 0.97 (0-3.31) n.a.
Episodes of acute infection per 
year
0.49 (0-2.51) n.a.
Hospitalization for asthma per 
year
0 (0-0.83) n.a.
Nocturnal dyspnoe per year 0.36 (0-3.16) n.a.
ICS [μg per day] 1258 (158-3289) n.a.
Oral GCS [mg per day] 1.6 (0-10.6) n.a.
Oral GCS [days of use per year] 76.4 (0-365) n.a.
Montelukast [mg per day] 2.3 (0-10) n.a.
Zafirlukast [mg per day] 0 (0-26.1) n.a.
Smokers [%] 20.5 16.6
Atopy [%] 63 0.0
GERD [%] 2.6 0.0
Chronic rhinosinusitis [%] 20.5 0.0
Aspirin intolerance [%] 10.2 0.0
Allergic rhinitis [%] 59 0.0
Variables are shown as median and range or percentage. n.a. - non 
applicable.BMC Immunology 2009, 10:63 http://www.biomedcentral.com/1471-2172/10/63
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CTG-3' and 5'-TCGGCAGCCAGCTCGTGAGTAATG-3',
for histone H3A - H3F3A: 5'-AGGACTTTAAAAGATCT-
GCGCTTCCAGAG-3' and 5'-ACCAGATAGGCCTCACTT-
GCCTCCTGC-3'. Gene expression levels of CysLT1
transcript I and II and two reference transcripts: RPS17,
and H3F3A were tested using the Rotor-Gene 3000 Real-
Time DNA analysis system (Corbett Research, Australia).
Cycling conditions: 1 cycle at 95°C for 10 min, 40 cycles
at 95°C for 30 s, 56°C for 15 s (CysLTR1 transcript I) or
65°C for 15 s (CysLT1 transcript II) or 64°C for 15 s
(RPS17) or 65°C for 15 s (H3F3A), and 72°C for 30 s. The
relative expression was based on the expression ratio of
the target gene versus reference genes (RPS17 and H3F3A).
To calculate the relative expression ratios of single sam-
ples a mathematical model was used which included an
efficiency correction for the real-time PCR efficiency of the
individual transcripts [30]. Relative expression was calcu-
lated using REST (Corbett Research, Australia) software
with the two reference genes mentioned above. Each
experiment was conducted in triplicate.
Statistical analysis
The data from the study were analyzed using Statistica (v.
6.0; StatSoft, Tulsa, OK). The distribution of all examined
variables was checked for normality. Because of the devi-
ation from normal distribution, in the analysis of alterna-
tive transcripts expression U-Mann-Whitney test was
performed to analyze differences between variables. Data
are expressed as mean relative expression ± SEM. Relation-
ship between alternative transcripts expression and stud-
ied asthmatic features were evaluated utilizing Spearman's
rank correlation test. Haplotype frequencies and linkage
disequilibria were estimated using the HaploView 4.0 pro-
gram [31]. Haplotypes of each individual were inferred by
using the algorithm developed by Stephens et al. (PHASE
version 2.1) [32]. The post-hoc analysis of the quantitative
variables with the Bonferroni correction was performed to
account for multiple testing.
Results
Study population
We analyzed the expression of CysLT1 alternative tran-
script I and II in 44 patients with asthma and 18 healthy
controls. Characteristics of study populations are shown
in Table 1. Haplotype distributions in both analyzed pop-
ulations are shown in Table 2. CAAC and TCGC were
dominant haplotypes in patients with asthma and in
healthy controls. The relative expression of CysLT1 tran-
script I in peripheral blood mononuclear cells was similar
in asthma (22.87 ± 5.93) and in healthy control group
(26.23 ± 12.98) (p > 0.05). Moreover, relative expression
of CysLT1 transcript II was lower than transcript I and also
similar in asthma (5.05 ± 0.84) and in controls (8.54 ±
2.41) (p > 0.05). Furthermore, the expression of these two
splice variants did not differ either between female
patients with asthma and female controls or male patients
vs male controls.
Alternative Transcripts-Haplotype Association Study
We hypothesized that the different expression of CysLT1
alternative transcripts might depend on the polymor-
phisms in the CYSLTR1 gene promoter region. Thus, we
performed an analysis concerning association of the
CysLT1 splice variants expression with the haplotypes in
each locus within the whole study population. We ana-
lyzed the differences between the two main haplotypes
CAAC and TCGC as they accounted for nearly 90% of the
studied populations, which was shown in Table 2. The
other haplotypes were too rare to perform appropriate
analysis. In women with asthma who are homozygotes in
Table 2: Haplotypes frequency in the asthmatic population (n = 44) and healthy subjects (n = 18)
Alleles C/T (rs321029) A/C (rs2637204) A/G (rs2806489) C/T (rs70667337) %
Asthmatic population (n = 44)
Haplotype
ht1 C A A C 75.4
ht2 T C G C 20.3
ht3 C A A T 1.4
ht4 C A G C 1.5
ht5 T C A C 1.4
Healthy subjects (n = 18)
Haplotype
ht1 C A A C 84
ht2 T C G C 12
ht3 C A A T 4
ht4 C A G C 0
ht5 T C A C 0BMC Immunology 2009, 10:63 http://www.biomedcentral.com/1471-2172/10/63
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major alleles in each analyzed locus CAAC/CAAC we
found significantly higher expression of transcript I 37.22
± 14.11 (pcor = 0.0169) and transcript I/II 13.38 ± 6.10
ratio (pcor = 0.009) as compared to heterozygous CAAC/
TCGC women in that loci, 4.08 ± 1.06 and 1.49 ± 0.65,
respectively (Figure 1, 2). We did not observe any differ-
ences in alternative transcripts expression in asthmatic
men with different promoter genotypes or in both sexes of
healthy patients.
CysLTR1 alternative transcripts correlations
We analyzed here correlations of CysLT1 alternative tran-
scripts expression with different features of asthma such as
FEV1, PEF, exacerbations, episodes of acute infection, hos-
pitalization for asthma, nocturnal dyspnoe and intake of
ICS, systemic GCS and LTRA in the whole asthmatic pop-
ulation. We observed weak but statistically significant
negative correlation of CysLT1 transcript I expression with
episodes of acute infection (R = - 0,52, pcor = 0.0009) (Fig-
ure 3). Relative expression of CysLT1 transcript II did not
correlate with any of studied asthmatic features.
Alternative Transcripts-Haplotype-Phenotype Association 
Study
We analyzed here if there are differences in CysLT1 splice
variants I and II expression in carriers of the same haplo-
types between asthmatic patients and healthy controls
with subsequent sex stratification. Again, we took into
consideration two main haplotypes CAAC and TCGC. We
observed that relative expression of CysLT1 transcript II in
CAAC/CAAC homozygotic women with asthma (3.86 ±
1.06) was significantly lower than in CAAC/CAAC healthy
control females (14.48 ± 6.90) (pcor = 0.019) (Figure 4).
There were no differences in case of CysLT1 transcript I
expression in either of analyzed configurations.
Discussion
Here we showed that there were no differences in CysLT1
alternative transcripts expression in the blood mononu-
clear cells between asthmatic patients and controls, when
they were evaluated as genetically homogeneous popula-
tions and without sex stratification. Figueroa et al found
that 20% of peripheral blood leukocytes showed the pres-
ence of CysLT1. These are cells of particular relevance to
CysLT1 transcript I relative expression in women with  asthma with two main CYSLTR1 haplotypes Figure 1
CysLT1 transcript I relative expression in women 
with asthma with two main CYSLTR1 haplotypes. Data 
are expressed as dots. Horizontal line represents mean. 
Asterisk indicates p < 0.05.
CysLT1 transcript I/II relative expression ratio in women with  asthma with two main CYSLTR1 haplotypes Figure 2
CysLT1 transcript I/II relative expression ratio in 
women with asthma with two main CYSLTR1 haplo-
types. Data are expressed as dots. Horizontal line repre-
sents mean. Asterisk indicates p < 0.05.
Correlation of CysLT1 transcript I relative expression with  the episodes of acute infection in the whole asthmatic popu- lation Figure 3
Correlation of CysLT1 transcript I relative expression 
with the episodes of acute infection in the whole 
asthmatic population. Spearman's rank correlation coeffi-
cient was R = - 0.52, pcor = 0.0009.BMC Immunology 2009, 10:63 http://www.biomedcentral.com/1471-2172/10/63
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asthma and atopy, such as monocytes/macrophages, eosi-
nophils, pregranulocytic CD34+ cells, neutrophils, and
subsets of B lymphocytes [33] and probably also T lym-
phocytes [17]. According to our best knowledge there has
been no data published comparing CysLT1  mRNA or
CysLT1  alternative transcripts expression in peripheral
blood mononuclear cells between asthmatic and healthy
subjects. There might be a few reasons of lack of differ-
ences in the overall CysLT1 mRNA expression at least in
the blood mononuclear cells. First of all, our patients were
in the stable period of the disease, without a trace of exac-
erbation in the moment of blood collection. Therefore,
inflammation might be present only locally in the bron-
chi, not in the peripheral blood, mainly because of the
persistent influx of inflammatory cells from the blood to
the bronchi. Zhu and colleagues found that there is an
increase of distinct inflammatory cells expressing the
CysLT1 receptor in the bronchial mucosa of mild asth-
matic patients as compared to healthy subjects and further
increase when there is a severe exacerbation of asthma
[18]. However they did not analyze peripheral blood [18].
Nevertheless, it might also confirm our main hypothesis
of indirect promoter SNPs influence on CYSLTR1 gene
transcription and/or alternative splicing in a sex related
manner. This might further correlate with the level of
CysLT1 protein expression and finally with the disease
phenotype. Several lines of evidence support this hypoth-
esis. First of all, we found that heterozygotic females
CAAC/TCGC with asthma had significantly lower expres-
sion of CysLT1 transcript I as compared to major female
asthmatic homozygotes CAAC/CAAC (Figure 1, 2). This
correlation was not observed in healthy women neither in
asthmatic and healthy men. In our previous study on the
association of these CYSLTR1 promoter SNPs with severe
asthma [26] in the population of 93 severe asthmatics,
110 non-severe asthmatics and 100 healthy controls we
showed that heterozygotic CAAC/TCGC females with
severe asthma had significantly more episodes of infec-
tion per year, more exacerbations per year, more hospital-
izations for asthma per year, and they used more ICS than
homozygotic female carriers of the main haplotype
CAAC/CAAC. However, we found no evidence on the
influence of these promoter SNPs on the gene expression
by means of reporter gene studies. Therefore, our current
findings might at least partially link this association with
the functional effects. Moreover, we showed here that
CysLT1 alternative transcripts expression might slightly
affect factors associated with the course of asthma. We
have observed the weak tendency that the more episodes
of acute respiratory infection per year in patients with
asthma (Figure 3) the lower expression of CysLT1 tran-
script I. However, the feeble distribution of data limits any
potential conclusions. Nevertheless, it could indicate on
the probability of impaired innate and afferent mecha-
nisms of acquired immune response in patients with
asthma, probably through altered CysLT1 receptor expres-
sion [6]. CysLTs and their receptors were proven to be crit-
ical determinants of dendritic cells homing to regional
lymph nodes and the repertoire of cytokines required to
induce T cell responses [34,35]. It was shown that matu-
ration of dendritic cells with LPS, a major endotoxin of
Gram-negative bacteria and a classic Toll-like receptor 4
agonist, reduced CysLT1 receptor expression by 50% [36].
Moreover, generation of leukotrienes from white blood
cells was enhanced during sepsis, and further increased
after stimulation but only in patients who survived this
massive infection [37]. This data might indicate the
importance of leukotrienes and their receptors not only in
the development of chronic inflammation in asthma but
also in episodes of acute respiratory infections, which are
one of the most important determinants of asthma exac-
erbations.
Episodes of acute respiratory infection in our study popu-
lation by means of symptoms and reaction to antibiotic
treatment fulfilled the definition of bacterial infection.
The limitation of this definition is lack of exact evidence
on bacterial or viral involvement. On the other hand, it
has been proven that viral infections, like respiratory syn-
cytial virus or parainfluenza virus, increase the level of
cysteinyl leukotrienes [38-40] and that antileukotriene
drugs alleviate symptoms of viral upper respiratory tract
infections [41,42]. The last but not least argument for our
initial hypothesis is that we have noticed that in CAAC/
CAAC women with asthma CysLT1 transcript II is differen-
tially expressed as compared to CAAC/CAAC healthy con-
trol women (Figure 4). Together with our previous
CysLTR1 transcript II expression in CAAC/CAAC asthmatic  and control females Figure 4
CysLTR1 transcript II expression in CAAC/CAAC 
asthmatic and control females. Data are expressed as 
dots. Horizontal line represents mean. Asterisk indicates p < 
0.05.BMC Immunology 2009, 10:63 http://www.biomedcentral.com/1471-2172/10/63
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findings that promoter SNPs did not influence its basal
activity, these data might suggest that there are other fac-
tors e. g. splicing factors, sex hormones or the effects of
some inflammatory cytokines that influence the CYSLTR1
gene transcription and/or splicing. It stays in agreement
with primarily contradictory findings of our and other
groups. Minor alleles of CYSLTR1  promoter SNPs
increased [24,25] or decreased [22] or demonstrated no
influence on the CYSLTR1 basic promoter activity [26].
Nowadays, there is an emerging consensus suggesting that
splicing is in most cases initiated cotranscriptionally and
that introns are removed while the nascent transcript is
still tethered to the DNA [43]. Some transcriptional coreg-
ulators, brought to the promoters by transcription factors,
either harbor splicing activity e.g. hnRNP [44] or interact
with spliceosome components [45]. Inversely, some pro-
teins like SKIP described initially as RNA-binding splicing
factors were later shown to be present at promoters and/
or to function as transcriptional regulators [46]. Four dif-
ferent mRNA CysLT1 transcripts were observed in human
cells, with the dominant expression of transcript I in both
unstimulated and IL-4 stimulated cells and far less abun-
dant expression of transcript II. Transcript III and IV were
found only in THP1 cell lines. However, the role of alter-
native transcripts of CysLT1 receptor has not been eluci-
dated [23]. They all form the same protein structure as the
coding region and ORF is included in the fifth exon,
present in each transcript. The putative CYSLTR1  pro-
moter was found to contain two STAT6 consensus
response elements, GATA and AP1 binding sites [23].
Four analyzed here CYSLTR1  promoter SNPs do not
change any known transcription factor binding sites, but
they might influence on the splicing binding factors.
Altered ratio of main transcripts I and II might further
influence on the expression status of structurally
unchanged receptor protein, not only in blood leukocytes
but also in inflammatory infiltration of the bronchi. This
subsequently could correlate with the phenotype. Ele-
vated expression of CysLT1 plays a role in asthma and its
exacerbation as shown Zhu et al [18]. Alternative splicing
of pre mRNA represents a widespread mechanism for
increasing variability of eukaryotic gene expression and
has been associated with human pathologies, such as can-
cer, Alzheimer's, amyotrophic lateral sclerosis, ataxia
teleangiectasia, cystic fibrosis, and other [47,48]. For
instance, non functional alpha subunit of the epithelial
sodium channel alternatively spliced forms have been
proposed to serve as negative regulatory components for
its activity in humans [49].
Finally, our previous and current data indicated the gen-
der differences in cysteinyl leukotrienes and their recep-
tors metabolic pathways. Female sex and a certain
haplotype might be a risk factor of the disease. Lack of the
TCGC haplotype effect on the CysLT1 alternative tran-
scripts expression in both asthmatic and healthy men
might suggest an additional effect of sex hormones or
some behavioral/environmental differences. Recently, it
has been shown in the large European multi-centered
cohort of patients that severe asthma occurs four times
more often in women that in men [50]. Moreover, in
accordance of our observations very recently Pergola et al
showed higher expression of 5-LO, 15-H(P)ETE and Cys-
LTs in stimulated whole blood and neutrophils in females
comparing to males accompanied with the differences in
5-LO cellular localization and trafficking [51]. These
effects were further abolished by male hormones testo-
sterone and 5-α-dihydrotestosterone [51]. Moreover, it
has been shown that estradiol modulates the pulmonary
influx of inflammatory cells, increases generation of IL-4
and mediates mast cell degranulation [52] while proges-
terone upregulates IL-4 production [53]. All of these
effects might increase the number of cells with CysLT1
receptor in the bronchial mucosa of female subjects.
Expression of CYSLTR1 gene may be also affected by expo-
sure to different proinflammatory cytokines. It has been
shown that CysLT1 may be upregulated in different cells
by proasthmatic cytokines such as IL-4, IL-5 and IL-13
[54] and the influence of analyzed haplotypes on gene
expression and alternative splicing may only be present
under specific inflammatory conditions.
In summary, still little is known about factors involved in
the processes of CYSLTR1 transcription, alternative splic-
ing, and their influence on the final CysLT1 receptor pro-
tein expression and further correlation with the asthma
phenotype. However, our data suggest that indeed
CYSLTR1 gene might be implicated in asthma pathogene-
sis at least by differential expression of CysLT1 alternative
transcripts in various haplotypes and in sex-related man-
ner, but the exact mechanisms remain to be clarified.
Conclusion
Genetic variants of CYSLTR1 promoter might be associ-
ated with gender specific expression of CysLT1 transcripts
in patients with asthma. CysLT1 splice variants expression
might also correlate with the susceptibility to infection in
asthmatic population.
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